Inclusive R&D: Shiru unites companies to unlock natural GLP-1 activation with AI tech

AI-powered ingredient discovery company Shiru launched the GLP-1 Innovation Alliance, inviting both Fortune 500 consumer packaged goods (CPG) companies and emerging brands to “collaborate as equals.” Shiru will grant businesses of all sizes access to its proprietary Flourish AI platform and library of over 33 million proteins to explore natural approaches to GLP-1 pathway activation.

The company says the alliance is a “radical departure” from traditional industry collaborations as these typically exclude smaller businesses from cutting-edge research opportunities. 

As health innovation is crucial but increasingly expensive, the company unveils this inclusive model that recognizes breakthroughs at a systemic level with diverse perspectives working together. 

“We’re doing something unconventional because conventional approaches aren’t meeting the urgency of our global health challenges,” says Dr. Jasmin Hume, founder and CEO of Shiru. “By bringing together CPG giants and emerging brands as equal partners in discovery, we’re creating a unique ecosystem where established resources meet entrepreneurial agility.” 

“This isn’t how our industry typically operates, and these aren’t typical times. The potential of natural GLP-1 activation is too important to limit to only those with the deepest pockets. As a company whose product development is fueled by AI, we understand that our greatest value comes not from hoarding data but from creating the ecosystem where that data can generate the most impact.”

GLP-1 Innovation Alliance

GLP-1 agonists have shown significant benefits in weight loss and metabolic health. The nutrition industry is developing products to complement these medications by filling in nutritional gaps or overcoming side effects associated with these drugs. Companies are also exploring natural alternatives. 

At the same time, Shiru says that the science of how food-derived compounds may influence GLP-1 pathways is “largely unexplored.” 

The company expects new breakthroughs in the field by combining its technology with diverse market insights, consumer understanding, and application expertise from consortium members. 

Shiru aims to create an ecosystem where CPG giants and emerging brands are equal partners in discovery with its AI platform.The alliance offers three engagement levels, ensuring that perspectives from billion-dollar brand managers and first-time founders alike can contribute to the discovery process. 

For its network, Shiru targets Discovery Leaders — companies ready to “deeply influence research direction” and access all findings with the first right to licensing. In addition, Innovation Partners can join for focused collaboration on specific applications, while Observer Members can stay connected to cutting-edge discoveries at an accessible price point. 

The application deadline for founding members is August 15, 2025. Shiru will give “special consideration” to companies that enhance the consortium’s diversity. The next opportunity to join the alliance will be in the Summer of 2026. 

Open-access approach

Shiru leverages AI’s inherent scalability and network effects in ingredient discovery, noting that the future of ingredient discovery lies in collective intelligence, diverse data inputs, and collaborative ecosystems. 

The company applies successful strategies from the software industry to ingredient discovery, where it says platform companies create more value through network effects and ecosystem development than closed-system approaches. 

Its Flourish platform has delivered a breakthrough in bioactive ingredients: sweet proteins that deliver sugar’s sweetness without the metabolic impact. The company partnered with Ajinomoto Health & Nutrition North America for this innovation. 

In texturizing innovations, the platform helped develop egg replacement proteins, methylcellulose alternatives, and uPro structuring protein. 

“We’ve invested years and millions of dollars building capabilities that are irreplicable at the individual company level,” says  Dr. Michael Madonna, Shiru’s vice president of research and development. 

“Our proprietary database, custom machine-learning models trained on actual performance data, and network of over 20 research partners prove that the complexity of this challenge demands collective action. Through this consortium, we demonstrate that true industry leadership means enabling everyone to succeed together.”

The company notes that these achievements demonstrate “what becomes possible when advanced AI meets biological complexity.”